MedPath

Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)

Phase 3
Completed
Conditions
Bipolar Depression
Interventions
Drug: Placebo
Registration Number
NCT00868699
Lead Sponsor
Sumitomo Pharma America, Inc.
Brief Summary

This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
505
Inclusion Criteria
  • Subject is diagnosed with bipolar I disorder, most resent episode depressed
  • Subject must have a lifetime history of at least one bipolar manic or mixed episode
Exclusion Criteria
  • History of nonresponse to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode
  • Subject has been hospitalized for a manic or mixed episode within 60 days prior to randomization
  • Imminent risk of suicide or injury to self, others, or property

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo-
lurasidone low armlurasidone-
lurasidone high armlurasidone-
Primary Outcome Measures
NameTimeMethod
Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)Baseline to Week 6

Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression.

The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.

The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.

Secondary Outcome Measures
NameTimeMethod
Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)Baseline to Week 6

Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) is a clinician-rated assessment of a subject's level of depression.

The CGI depression score ranges from a minimum of 0 to a maximum of 7. For the CGI depression score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.

Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total ScoreBaseline to Week 6

Sheehan Disability Scale (SDS) total score is a subject-rated assessment of a subject's level of depression.

The SDS total score ranges from a minimum of 0 to a maximum of 30. For the SDS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.

The SDS contains three (3) items. The total score is computed as the sum of the scores for the 3 items.

Trial Locations

Locations (55)

CRI Worldwide, LLC

🇺🇸

Philadelphia, Pennsylvania, United States

Mood Disorders Program-UHCMC

🇺🇸

Cleveland, Ohio, United States

R.K. Yadav Memorial Mental Health & De-Addiction Hospital

🇮🇳

Jaipur, Rajasthan, India

Reg Cl.Ps.H.n.a.O.F. Malstev, Fem.Ac. Gen. Ps.D.5B

🇺🇦

Poltava, Ukraine

American Medical Research Inc.,1200 Harger Road Suite 415

🇺🇸

Oak Brook, Illinois, United States

Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340

🇺🇸

Lake Charles, Louisiana, United States

California Neuropsychopharmacology Clinical Research Institute, LLC,466 26th Street,6th Floor

🇺🇸

San Diego, California, United States

Florida Clinical Research Center, LLC,3914 State Road 64 East

🇺🇸

Bradenton, Florida, United States

Zans Ritter, Marcel

🇫🇷

Orvault, France

Vijayawada Institute of Mental Health and Neurosciences, Psychiatry

🇮🇳

Vijaywada, Andh Prad, India

Janus Center for Psychiatric Research,5601 Corporate Way,Suite 103

🇺🇸

West Palm Beach, Florida, United States

BIALBI s.r.o., Psychiatricke Oddeleni

🇨🇿

Litomerice, Czech Republic

Clintrial, s.r.o.

🇨🇿

Praha, Czech Republic

S V Medical College

🇮🇳

Tirupati, Andh Prad, India

Finger Lakes Clinical Research

🇺🇸

Rochester, New York, United States

Hopital Caremeau, Service de Psychiatrie A

🇫🇷

Nimes Cedex, France

Samvedna Hospitals

🇮🇳

Ahmedabad, Gujarat, India

Spitalul Clinic Judetean de Urgenta Cluj

🇷🇴

Cluj-Napoca, Romania

Vereeniging Medi-Clinic

🇿🇦

Vereeniging, Free State, South Africa

Paarl Medical Centre

🇿🇦

Paarl, W. Cape, South Africa

Clinika

🇿🇦

Port Elizabeth, E. Cape, South Africa

Dey Clinic

🇿🇦

Pretoria, Gauteng, South Africa

Spandana Nursing Home

🇮🇳

Bangalore, Karna, India

Spitalul Clinic de Neuropsihiatrie Craiova

🇷🇴

Craiova, Romania

City Psychiatric Hospital #2 of St. Nikolay Chudotvorets

🇷🇺

St. Petersburg, Russian Federation

Spitalul Clinic de Urgenta Militar Central

🇷🇴

Bucdresti, Romania

Spitalul Clinic de Neurologie si Psihiatrie Oradea

🇷🇴

Oradea, Romania

Reg. Psychiatric Hospital

🇺🇦

Odessa, Ukraine

Reg. Psych. Hosp.n.a.O.Yuschenko, Dept #21

🇺🇦

Vinnitsia, Ukraine

University of California at Irvine Medical Center

🇺🇸

Orange, California, United States

Excell Research, Inc,3998 Vista Way,Suite 100

🇺🇸

Oceanside, California, United States

California Neuropsychopharmacology,CNRI - Los Angeles LLC,8309 Telegraph Road

🇺🇸

Pico Rivera, California, United States

Sheppard Pratt Health System,6501 North Charles Street

🇺🇸

Baltimore, Maryland, United States

Neurobehavioral Research, Inc.

🇺🇸

Cedarhurst, New York, United States

Psychiatricka ambulance

🇨🇿

Brno - mesto, Czech Republic

Medical Services Prague s.r.o.

🇨🇿

Kolejni 429-5, Praha, Czech Republic

Spitalul Clinic de Psihaiatrie Prof. Dr. Alexandru Obregia

🇷🇴

Bucuresti, Romania

Seth K M School of P G Medicine & Research

🇮🇳

Ahmedabad, Gujarat, India

Sujata Birla Hospital & Research Centre

🇮🇳

Nashik, Mahara, India

Manobal Med. Research Centre

🇮🇳

Lucknow, Uttar Prad, India

Cape Trial Centre

🇿🇦

Cape Town, W. Cape, South Africa

Bekhterev Scientific Research Psychoneurological Institute

🇷🇺

St. Petersburg, Russian Federation

CRI Cl.Psych.Hosp. #1, Fem. Psych. Dept. #2, Male I

🇺🇦

Simferopol, Ukraine

Collaborative Neuroscience Network Inc.,12772 Valley View Street,Suite 3

🇺🇸

Garden Grove, California, United States

Synergy Escondido,710 East Grand Ave.

🇺🇸

Escondido, California, United States

Florida Clinical Research Center, LLC,2300 Maitland Center Parkway,Suite 230

🇺🇸

Maitland, Florida, United States

Depression and Anxiety Disorders Research Institute

🇺🇸

Tampa, Florida, United States

Albuquerque Neuroscience Inc., 101 Hospital Loop, NE, Suite 209

🇺🇸

Albuquerque, New Mexico, United States

Richard H. Weisler., M.D., P.A., & Associates,700 Spring Forest Road,Suite 125

🇺🇸

Raleigh, North Carolina, United States

MetroHealth System

🇺🇸

Cleveland, Ohio, United States

FutureSearch Clinical Trials, LLC.,4200 Marathon Blvd.,Suite 200

🇺🇸

Austin, Texas, United States

Chair of Psychiatry and Medical Psychology

🇺🇦

Donetsk, Ukraine

Psychoneurology Dispensary #4

🇷🇺

St. Petersburg, Russian Federation

University of Colorado

🇺🇸

Aurora, Colorado, United States

Mental Illness Treatment Rehabilitationi Foundation

🇮🇳

Ahmedabad, Gujarat, India

© Copyright 2025. All Rights Reserved by MedPath